2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 928

The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells
Abstract Number: 1669

The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
Abstract Number: 1062

The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
Abstract Number: 2514

The Brief Index of Lupus Damage, a Patient-Reported Measure of Lupus Damage, Is Sensitive to Change
Abstract Number: 1850

The Bromodomain Protein Inhibitor I-BET151 Suppresses Inflammatory and Matrix Degrading Properties Of Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2911

The Challenge To Develop a Multidimensional Computerized Adaptive Test For Fatigue In Rheumatoid Arthritis
Abstract Number: 1817

The Clinical Burden Of Generalized Osteoarthritis Represented By Activity Limitations and Health Related Quality Of Life: A Cross-Sectional Study
Abstract Number: 2755

The Clinical Significance and Natural History Of Knee Bone Marrow Lesions Over 8 Years
Abstract Number: 2919

The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Abstract Number: 2553

The Clinical Value Of Testing For Aphl, a New ELISA Kit With a Unique Phospholipid Mixture In Patients With Systemic Lupus Erythematosus (SLE)
Abstract Number: 2022

The Comparison Between IgG4-Related Retroperitoneal Fibrosis and Idiopathic Retroperitoneal Fibrosis
Abstract Number: 228

The Composition and Structure Of Calcifications In Juvenile Dermatomyositis Differs From Calcified Aortic Valves Removed From Adults Without JDM
Abstract Number: 2444

The Contribution Of Disease Activity On Function and Quality Of Life In Patients With Ankylosing Spondylitis; Investigating Causality By Using Structural Equation Model
Abstract Number: 1773

The Contribution Of Environmental Factors To Familial Risk Of Rheumatoid Arthritis By Serologic Phenotypes Among Women In a Longitudinal Cohort Study
Abstract Number: 118

The Controversies and Points Of Debate That Remain a Challenge For Fibromyalgia Care

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].